High-Dose Chemotherapy With Autologous Stem-Cell Rescue In Pediatric Patients With CNS Tumors: Toxicity And Outcomes

Abstract

We report the outcomes of all pediatric patients who received high-dose chemotherapy with autologous stem cell rescue for craniospinal (CNS) tumors at our institution. Thirty-two patients underwent 38 autologous transplants between 2002 and 2009. The population included 15 males and 17 females with a median age of 66 months at diagnosis and 87 months at transplant. The underlying diseases were medulloblastoma (56%), PNET (25%), ATRT (13%), and pinealoblastoma (6%). Thirty-seven percent of patients were treated for high-risk disease upfront, whereas 63% were treated for recurrent or progressive disease.